Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREE-study
2024-516277-68-00Phase 4Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of adalimumab and infliximab in Crohn's disease and autoimmune colitis, sponsored by University Medical Center Groningen. Primary endpoint: Cumulative incidence of out-of-range faecal calprotectin at 48 weeks. Planned start Sep 2024; status: authorised.
02
Drugs
adalimumabinfliximab
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2024-516277-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516277-68-00.